eligibility_summary
Adults 18–69 with CD70+ advanced RCC after VEGFR-targeted and immune checkpoint therapy, ≥1 measurable lesion <6 cm, ECOG ≤2, life expectancy ≥12 wks, adequate blood counts, liver/renal function, LVEF ≥50%, SpO2 >93%, normal coag, good venous access, contraception. Exclude prior CAR‑T/anti‑CD70, transplant, active serious infection (HBV/HCV/HIV/syphilis), serious CNS/cardiac/pulmonary/autoimmune disease, high-dose steroids, recent major surgery, unresolved AEs, pregnancy/breastfeeding.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Intervention: anti-CD70 CAR-T cells—autologous, gene‑modified T lymphocytes engineered with a CD70‑specific chimeric antigen receptor, given as a single IV infusion after lymphodepleting chemotherapy (fludarabine + cyclophosphamide, dose levels 3×10^6–2×10^7 cells/kg). Mechanism of action: CAR binding to CD70 triggers T‑cell activation, cytokine release, and perforin/granzyme‑mediated cytotoxicity against CD70+ tumor cells, lymphodepletion reduces host lymphocytes/cytokine sink to enhance CAR‑T expansion (fludarabine is a purine analog, cyclophosphamide an alkylator). Targets: CD70 on renal cell carcinoma (CD70/CD27 axis) and downstream T‑cell signaling/cytolytic pathways. Population: adults with inoperable, CD70+ advanced/relapsed RCC post VEGFR‑targeted and checkpoint therapy.